Microalbuminuria Use in primary care and importance in the cardiorenal axis
(05:10 /15:22)
Outline
1. BK Virus-Induced Nephropa
2. Relevance of topic
3. Objectives
4. Background:BK Virus
5. Background:BK Virus
6. Epiderniology
7. Life Cycle
8. Pathophysiology
9. Life Cycle
10. Pathophysiology
11. Risk Factors
12. Risk Factors
13. BK Virus-Induced Nephrop
14.
15. Diagnosis
16. Urine Decoy Cells
17. Serology
18. Type and prevalence of B
19.
20.
21. Diagnosis
22. Stages of BKVN
23. Biopsy
24. Biopsy of BKVN
25. Histology
26. IHC:SV 40-T Ag Detection
27. Randhawa et al. 2006. Am
28. Treatment
29. Efficacy of ISSN Reducti
30.
31. Results
32. Efficacy of ISSN Reducti
33.
34.
35. Immunosuppression Reduct
36. Treatment
37. Adjuvant Tx: Leflunomide
38. Adjuvant Therapies: Cido
39. Adjuvant Therapies
40.
41. Retransplantation
42. Postinfection Monitoring
43. Prognosis
44. BK Monitoring Algorithm
45. Key Points
46.
Thumbnails
1. BK Virus-Induced Nephropa
2. Relevance of topic
3. Objectives
4. Background:BK Virus
5. Background:BK Virus
6. Epiderniology
7. Life Cycle
8. Pathophysiology
9. Life Cycle
10. Pathophysiology
11. Risk Factors
12. Risk Factors
13. BK Virus-Induced Nephrop
14.
15. Diagnosis
16. Urine Decoy Cells
17. Serology
18. Type and prevalence of B
19.
20.
21. Diagnosis
22. Stages of BKVN
23. Biopsy
24. Biopsy of BKVN
25. Histology
26. IHC:SV 40-T Ag Detection
27. Randhawa et al. 2006. Am
28. Treatment
29. Efficacy of ISSN Reducti
30.
31. Results
32. Efficacy of ISSN Reducti
33.
34.
35. Immunosuppression Reduct
36. Treatment
37. Adjuvant Tx: Leflunomide
38. Adjuvant Therapies: Cido
39. Adjuvant Therapies
40.
41. Retransplantation
42. Postinfection Monitoring
43. Prognosis
44. BK Monitoring Algorithm
45. Key Points
46.
Notes
MAU: Summary
Time: 01 min 17 sec
Search
Search in
Slide text
Slide notes
Slide titles
References
Slide
01
/46
00:00
/ 03:50
